Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.77 |
| ▸ | HRH1 | P35367 | 11/20 | 0.77 |
| ▸ | HRH2 | P25021 | 7/20 | 0.68 |
| ▸ | HTR1A | P08908 | 5/20 | 0.64 |
| ▸ | DRD2 | P14416 | 5/20 | 0.64 |
| ▸ | HTR2A | P28223 | 5/20 | 0.64 |
| ▸ | DRD3 | P35462 | 5/20 | 0.64 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | DRD5 | P21918 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1714405 | 0.94 | HRH3 (0.74) | HRH3HRH1HRH2HTR1ADRD2 | |
| SCHEMBL1715391 | 0.91 | HRH3 (0.84) | HRH3HRH1HRH2 | |
| SCHEMBL5623066 | 0.88 | HRH3 (0.79) | HRH3HRH1HRH2 | |
| SCHEMBL14393458 | 0.86 | HRH3 (0.88) | HRH3HRH1HRH2 | |
| SCHEMBL1714440 | 0.86 | HRH3 (0.88) | HRH3HRH1HRH2 | |
| SCHEMBL23097577 | 0.85 | HRH3 (0.59) | HRH3HRH1HRH2HTR1ADRD2 | |
| SCHEMBL7295095 | 0.85 | HRH3 (0.75) | HRH3HRH1HRH2DRD3 | |
| Hydrochloric Acid SCHEMBL1714618 | 0.85 | HRH3 (0.86) | HRH3HRH1HRH2 | |
| SCHEMBL491845 | 0.84 | HRH3 (0.97) | HRH3HRH1HRH2 | |
| SCHEMBL24324260 | 0.84 | HRH3 (0.73) | HRH3HRH1HRH2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1481966-A1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | SLC7A1, NAT1, NACA | HRH3 395/4885HRH1 386/4885HRH2 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.